JO3654B1 - مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) - Google Patents

مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)

Info

Publication number
JO3654B1
JO3654B1 JOP/2016/0085A JOP20160085A JO3654B1 JO 3654 B1 JO3654 B1 JO 3654B1 JO P20160085 A JOP20160085 A JO P20160085A JO 3654 B1 JO3654 B1 JO 3654B1
Authority
JO
Jordan
Prior art keywords
benzimidazoles
aza
receptor modulators
ampa receptor
compounds
Prior art date
Application number
JOP/2016/0085A
Other languages
English (en)
Inventor
M Savall Bradley
Wu Dongpei
M Swanson Devin
Patrick Lebold Terry
K Ameriks Michael
G B Berry Cynthia
Loic Jourdan Fabrice
Angel Pena Pi??N Miguel
Chen Gang
Ravula Suchitra
Wei LIN David
Zhang Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3654B1 publication Critical patent/JO3654B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتوفر بهذا الاختراع مركبات بالصيغة (I) وأملاحها المقبولة صيدلانيًا أو أكاسيدها النيتروجينية أو تذاوباتها، (I) يتوفر بهذا الاختراع أيضًا مركبات صيدلانية تتضمن مركبات بالصيغة (I) وطرق استخدام مركبات بالصيغة (I).
JOP/2016/0085A 2015-04-29 2016-04-28 مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) JO3654B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
JO3654B1 true JO3654B1 (ar) 2020-08-27

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0085A JO3654B1 (ar) 2015-04-29 2016-04-28 مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)

Country Status (39)

Country Link
US (5) US11312712B2 (ar)
EP (3) EP3288940B9 (ar)
JP (2) JP6800886B2 (ar)
KR (2) KR20170140382A (ar)
CN (1) CN107835814B (ar)
AR (1) AR104447A1 (ar)
AU (2) AU2016255434C1 (ar)
BR (2) BR122023023802A2 (ar)
CA (1) CA2983826A1 (ar)
CO (1) CO2017011017A2 (ar)
CR (1) CR20170484A (ar)
CY (1) CY1124059T1 (ar)
DK (1) DK3288940T5 (ar)
EA (1) EA033281B1 (ar)
EC (1) ECSP17074645A (ar)
ES (1) ES2865330T3 (ar)
GT (1) GT201700231A (ar)
HR (1) HRP20210403T1 (ar)
HU (1) HUE053943T2 (ar)
IL (1) IL254848B (ar)
JO (1) JO3654B1 (ar)
LT (1) LT3288940T (ar)
MA (1) MA41988B1 (ar)
MD (1) MD3288940T2 (ar)
MX (1) MX376113B (ar)
MY (1) MY194104A (ar)
NI (1) NI201700129A (ar)
PH (1) PH12017501816B1 (ar)
PL (1) PL3288940T3 (ar)
PT (1) PT3288940T (ar)
RS (1) RS61688B1 (ar)
SG (1) SG11201708190UA (ar)
SI (1) SI3288940T1 (ar)
SM (1) SMT202100222T1 (ar)
TW (1) TWI706952B (ar)
UA (1) UA120304C2 (ar)
UY (1) UY36654A (ar)
WO (1) WO2016176460A1 (ar)
ZA (1) ZA201708065B (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023038A2 (pt) * 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
KR20170140382A (ko) 2015-04-29 2017-12-20 얀센 파마슈티카 엔.브이. 아자벤즈이미다졸 및 ampa 수용체 조절제로서의 이의 용도
EP3641768B1 (en) 2017-06-21 2025-12-31 iCell Gene Therapeutics LLC Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) * 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
JP7250687B2 (ja) * 2017-10-06 2023-04-03 武田薬品工業株式会社 複素環化合物
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
CA3129067A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法
CN117402148A (zh) * 2023-07-26 2024-01-16 青岛大学 一种氮-氮苯并咪唑轴手性化合物及其制备方法和应用
WO2025155830A1 (en) 2024-01-17 2025-07-24 Rapport Therapeutics, Inc. Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy
TW202539660A (zh) * 2024-01-17 2025-10-16 南韓商Ｌｇ化學股份有限公司 作為ＣＢＰ／ｐ３００抑制劑之新穎化合物和含有彼作為活性成分以預防或治療癌症、發炎病症或自體免疫疾病之醫藥組成物
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof
WO2025231416A1 (en) * 2024-05-03 2025-11-06 Rapport Therapeutics, Inc. Methods of use of ampa receptor modulators

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (ar) * 1992-11-02 1995-07-11 Pfizer
JP2829788B2 (ja) 1994-02-10 1998-12-02 ファイザー インク． ベンゾジアゼピン受容体部位アゴニスト及びアンタゴニストとしての５−ヘテロアリールインドール誘導体
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
WO1999045007A1 (en) 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo[4,3-b]pyridines
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP1100504A2 (en) * 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
US7842698B2 (en) * 2004-09-03 2010-11-30 Merck Serono S.A. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
EA016286B1 (ru) 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
EP2086643B1 (en) 2006-11-03 2011-03-23 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
US20110312938A1 (en) * 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
PH12012501621A1 (en) 2010-02-11 2012-10-22 Univ Vanderbilt Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
TWI546302B (zh) 2010-06-24 2016-08-21 武田藥品工業股份有限公司 稠合雜環化合物
PE20131116A1 (es) 2010-08-10 2013-10-24 Takeda Pharmaceutical Compuestos heterociclicos potenciadores de ampa
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
CA2900302C (en) 2013-02-19 2018-07-03 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
KR20170140382A (ko) 2015-04-29 2017-12-20 얀센 파마슈티카 엔.브이. 아자벤즈이미다졸 및 ampa 수용체 조절제로서의 이의 용도
EP3532476B1 (en) 2016-10-26 2020-08-19 Janssen Pharmaceutica NV Fused azaheterocyclic compounds and their use as ampa receptor modulators
WO2018080918A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators
EP3532477B1 (en) 2016-10-26 2020-08-26 Janssen Pharmaceutica NV Fused bicylic pyridine compounds and their use as ampa receptor modulators
WO2019198692A1 (en) 2018-04-09 2019-10-17 Raqualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途

Also Published As

Publication number Publication date
US20250230157A1 (en) 2025-07-17
EP3288940A1 (en) 2018-03-07
SMT202100222T1 (it) 2021-05-07
HRP20210403T1 (hr) 2021-10-29
EP4144736A1 (en) 2023-03-08
HUE053943T2 (hu) 2021-08-30
PL3288940T3 (pl) 2021-07-12
TW201708217A (zh) 2017-03-01
ECSP17074645A (es) 2018-02-28
WO2016176460A1 (en) 2016-11-03
EP3288940B9 (en) 2021-07-21
EA033281B1 (ru) 2019-09-30
US11312712B2 (en) 2022-04-26
MX376113B (es) 2025-03-07
MX2017013886A (es) 2018-03-12
SG11201708190UA (en) 2017-11-29
CN107835814B (zh) 2021-07-23
CA2983826A1 (en) 2016-11-03
EP3901153A1 (en) 2021-10-27
TWI706952B (zh) 2020-10-11
US20230114165A1 (en) 2023-04-13
UA120304C2 (uk) 2019-11-11
SI3288940T1 (sl) 2021-07-30
RS61688B1 (sr) 2021-05-31
AU2016255434B2 (en) 2020-05-14
US12304908B2 (en) 2025-05-20
MA41988A (fr) 2018-07-03
KR20240017991A (ko) 2024-02-08
GT201700231A (es) 2018-12-20
EA201792374A1 (ru) 2018-05-31
MA41988B1 (fr) 2021-03-31
AU2020210231A1 (en) 2020-08-20
US20210284641A1 (en) 2021-09-16
ZA201708065B (en) 2019-09-25
LT3288940T (lt) 2021-05-10
DK3288940T3 (da) 2021-05-25
NZ736057A (en) 2023-08-25
DK3288940T5 (da) 2021-09-20
AR104447A1 (es) 2017-07-19
BR112017023147A2 (pt) 2018-07-10
AU2016255434A1 (en) 2017-10-26
KR102782808B1 (ko) 2025-03-14
KR20170140382A (ko) 2017-12-20
AU2020210231B2 (en) 2021-07-22
AU2016255434C1 (en) 2021-09-23
US12145934B2 (en) 2024-11-19
BR112017023147B1 (pt) 2024-04-30
PT3288940T (pt) 2021-04-30
CN107835814A (zh) 2018-03-23
CR20170484A (es) 2018-02-26
BR122023023802A2 (pt) 2023-12-26
NZ774642A (en) 2024-09-27
PH12017501816B1 (en) 2023-07-19
JP2018518462A (ja) 2018-07-12
HK1252249A1 (en) 2019-05-24
US20180118740A1 (en) 2018-05-03
NI201700129A (es) 2019-05-10
JP6800886B2 (ja) 2020-12-16
JP2021042230A (ja) 2021-03-18
ES2865330T3 (es) 2021-10-15
US20230110576A1 (en) 2023-04-13
IL254848A0 (en) 2017-12-31
US12139485B2 (en) 2024-11-12
CO2017011017A2 (es) 2018-03-20
MD3288940T2 (ro) 2021-08-31
IL254848B (en) 2021-01-31
UY36654A (es) 2016-10-31
MY194104A (en) 2022-11-11
CY1124059T1 (el) 2022-05-27
JP7026194B2 (ja) 2022-02-25
EP3288940B1 (en) 2021-02-24
PH12017501816A1 (en) 2018-04-23

Similar Documents

Publication Publication Date Title
JO3654B1 (ar) مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)
JOP20190174B1 (ar) مثبطات jak1 انتقائية
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
EA201591420A1 (ru) Гетероарильные соединения и их применение
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
MX375184B (es) Inhibidores de prmt5 y sus usos.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
TW201613864A (en) Novel compounds
MX378389B (es) Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MX384798B (es) Piridinona dicarboxamida para uso como inhibidores de bromodominio.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина